MedPath

Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder

Phase 2
Completed
Conditions
Major Depressive Disorder
Registration Number
NCT00290914
Lead Sponsor
Pharmacology Research Institute
Brief Summary

The purpose is to evaluate the safety and usefulness of the investigational drug, vilazodone in depression.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Male or female patients 18-65 years of age, inclusive.
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath